title: Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
abstract: In the upcoming case of Teva Pharmaceuticals v. Sandoz, the U.S. Supreme Court will address how much deference the appellate court should afford to a trial court's claim construction ruling. The effect of this decision will be far-reaching, as how claims are construed can determine whether a patent is infringed or not infringed, valid or invalid.
authors.affiliation: 1Partner, Jenner & Block LLP , 353 N Clark St., Chicago, IL 60654 , USA +1 312 923 2661 ; +1 312 923 2761 ; lfogel@jenner.com.
authors.forename: Louis E
authors.initials: LE
authors.lastname: Fogel
authors.forename: Chad J
authors.initials: CJ
authors.lastname: Ray
mesh_terms: D003132:Commerce / Q000191:economics / Q000331:legislation & jurisprudence*; D016527:Drug Costs / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control / Q000191:economics / Q000331:legislation & jurisprudence*; D016568:Drugs, Generic / Q000191:economics / Q000600:supply & distribution*; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics / Q000600:supply & distribution*; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D010455:Peptides / Q000191:economics / Q000600:supply & distribution*; D014481:United States
chemical_list: D016568:Drugs, Generic; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate
keywords: Copaxone®; at-risk launch; claim construction; patent expiration; patent litigation